CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


AVIGAN 200 mg Film TabletsWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (3)


Name (Synonyms) Correlation
drug1825 Placebo (Plasma-Lyte 148) Wiki 1.00
drug906 FAVICOVIR 200 mg Film Tablet Wiki 1.00
drug1080 Human umbilical cord derived CD362 enriched MSCs Wiki 1.00

Correlated MeSH Terms (4)


Name (Synonyms) Correlation
D013577 Syndrome NIH 0.11
D055371 Acute Lung Injury NIH 0.10
D012127 Respiratory Distress Syndrome, Newborn NIH 0.10
D012128 Respiratory Distress Syndrome, Adult NIH 0.09

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials


1 Open-label,Randomised,Single Oral Dose,Two-period,Cross-over Trial to Assess to Bioequivalence of Favicovir 200 mg FT in Comparison With Avigan 200 mg FT in Healthy Male Subjects Under Fasting Conditions

A single dose of Reference product containing 200 mg favipiravir and a single dose of Test product containing 200 mg favipiravir or vice versa; administered with 240 mL of water at room temperature, in each period under fasting conditions with current pandemic precautions.

NCT04406194 Bioequivalence Drug: FAVICOVIR 200 mg Film Tablet Drug: AVIGAN 200 mg Film Tablets

Primary Outcomes

Description: Area under the concentration-time curve of favipiravir in plasma over the time interval from 0 to 24 hours

Measure: AUC0-tlast of Favipiravir

Time: 0 to 24 hours post-dose

Description: Maximum plasma concentration of favipiravir

Measure: Cmax of Favipiravir

Time: 0 to 24 hours post-dose

Secondary Outcomes

Description: Area under the plasma concentration curve to infinite time of favipiravir

Measure: AUC0-inf of Favipiravir

Time: 0 to 24 hours post-dose

Description: Time to reach maximum plasma concentration of favipiravir

Measure: Tmax of Favipiravir

Time: 0 to 24 hours post-dose


No related HPO nodes (Using clinical trials)